title: Neural synchrony in patients with a first episode of schizophrenia: tracking relations with grey matter and symptom profile.
abstract: BACKGROUND
  Although schizophrenia has been characterized by disruptions to neural synchrony, it remains unknown whether these disturbances are related to symptoms and loss of grey matter. We examined relations between 40 Hz Gamma band synchrony and grey matter in patients with schizophrenia at first episode and after 2.5 years.
  
  
  METHODS
  From an initial recruitment of 35 medicated patients with a first episode of schizophrenia, 25 patients completed clinical and oddball task-elicited Gamma synchrony within 3 months of health service contact and again after 2.5 years, 23 completed magnetic resonance imaging (MRI) at these time points, and 13 completed all sessions. We compared patients with 35 matched healthy controls. We identified early (0-150 ms) and late (250-500 ms) peaks in Gamma synchrony locked to oddball targets, and we analyzed MRI data using voxel-based morphometry. We evaluated group and test-retest differences using repeated-measures analyses of variance.
  
  
  RESULTS
  Compared with controls, at first contact, patients with a first episode of schizophrenia showed a disruption to the laterality of early Gamma synchrony and global reduction in late Gamma synchrony, with a corresponding loss of fronto-temporal-parietal grey matter. Gamma synchrony was increased at follow-up among patients with a first episode of schizophrenia. It related negatively to further loss of grey matter, but positively to improvement in reality distortion symptoms. These relations could not be explained by medication dose.
  
  
  CONCLUSIONS
  Our study did not include unmedicated patients or normative follow-up testing.
  
  
  CONCLUSIONS
  Gamma synchrony may track the progression of schizophrenia from first episode. An increase in Gamma synchrony over time might reflect an attempt to adapt to a progressive loss of cortical grey matter and associated changes in cognitive and emotional function.
authors.affiliation: Brain Dynamics Centre, Westmead Millennium Institute and Western Clinical School, University of Sydney, Westmead, Sydney, Australia. lea@psych.usyd.edu.au
authors.forename: Leanne M
authors.initials: LM
authors.lastname: Williams
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Whitford
authors.forename: Evian
authors.initials: E
authors.lastname: Gordon
authors.forename: Lavier
authors.initials: L
authors.lastname: Gomes
authors.forename: Kerri J
authors.initials: KJ
authors.lastname: Brown
authors.forename: Anthony W F
authors.initials: AW
authors.lastname: Harris
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000473:pathology*; D002648:Child; D003627:Data Interpretation, Statistical; D004569:Electroencephalography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D011597:Psychomotor Performance / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents